Mitoconix Bio, an innovative Israeli startup bred by Israel’s only life science incubator, FutuRx, has recently raised $20 million to develop a promising drug for the treatment of Huntington’s disease
Continue Reading Greenberg Traurig Client Mitoconix Bio to Take Aim at Huntington’s Disease